Sub-Saharan Africa branded generics: Strides Pharma agrees Sandoz acquisition for USD 12 million
Strides Pharma Science has signed definitive agreements with Sandoz AG to acquire selected branded generic products across Sub-Saharan Africa for an upfront USD 12 million, payable at closing, plus royalties linked to net sales. The deal covers Western Sahara, Ghana, Nigeria, and Kenya, and is expected to close by end of Q2 FY27.
Business
Strides Pharma Science said on Tuesday it agreed with Sandoz AG to buy certain branded generic products in Sub-Saharan Africa. Strides Pharma International AG (SPIAG) signed definitive agreements with Sandoz AG, Switzerland, and group entities. The deal covers products sold through distribution in several African markets.
Strides Pharma Science told regulators the upfront payment is USD 12 million. The amount is payable at closing. The agreement also includes royalty payments to Sandoz. Royalties are linked to a percentage of net sales from distribution products.
Strides Pharma Science deal timeline and structure
The company said the transaction is expected to close by the end of Q2 FY27. Strides Pharma Science did not change that timeline in the filing. The structure includes an upfront amount and future royalties. The royalties depend on sales after the takeover.
Strides Pharma Science markets covered in Sub-Saharan Africa
The agreement spans four key markets in the region. It includes Western Sahara, which covers 10 countries. The other markets named were Ghana, Nigeria, and Kenya. Strides Pharma Science said the products involved are part of Sandoz’s branded generics business.
Strides Pharma Science products and therapy areas
The branded generics portfolio includes several brands across key therapy segments. Strides named anti-infective, cardiovascular, and dermatology categories. The company said several products each record more than USD 1 million in annual sales. It linked those sales to brand strength and steady demand.
Strides Pharma Science expected position after Sandoz portfolio buy
Strides said the purchase, combined with existing business, could lift its standing in the region. Strides expects to rank among the top five pharmaceutical companies in the SSA region by sales. The company also said it expects to be among the top two in the representable market.
With inputs from PTI
